Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE Study

被引:0
|
作者
Teixeira, Maria Margarida [1 ]
Dias, Joao [2 ]
Andre, Teresa [3 ]
Joaquim, Ana [4 ]
Fernandes, Ricardo [5 ]
Magalhaes, Joana [6 ]
Marreiros, Laura [7 ]
Pinto, Leonor [8 ]
Ribeiro, Leonor [9 ]
Nogueira, Mafalda [10 ]
Morais, Catarina [10 ]
机构
[1] Inst Portugues Oncol Coimbra Francisco Gentil, P-3000075 Coimbra, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, P-4200072 Porto, Portugal
[3] Hosp Dr Nelio Mendonca, P-9000177 Funchal, Portugal
[4] Unidade Local Saude Gaia Espinho, P-4434502 Vila Nova De Gaia, Portugal
[5] Unidade Local Saude Braga, P-4710243 Braga, Portugal
[6] Unidade Local Saude Algarve, P-8000386 Faro, Portugal
[7] Unidade Local Saude Almada Seixal, P-2805267 Almada, Portugal
[8] Unidade Local Saude Coimbra, P-3004561 Coimbra, Portugal
[9] Unidade Local Saude Santa Maria, P-1649035 Lisbon, Portugal
[10] MSD Portugal, Paco De Arcos, Portugal
关键词
head and neck; recurrent or metastatic disease; real-world; healthcare resources; patient management; SQUAMOUS-CELL CARCINOMA; GUIDELINES(R) INSIGHTS HEAD; RECURRENT/METASTATIC HEAD; PEMBROLIZUMAB; CHEMOTHERAPY; EPIDEMIOLOGY; KEYNOTE-048; CETUXIMAB; RISK;
D O I
10.3390/curroncol31080318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50-69 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (>70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.
引用
收藏
页码:4270 / 4283
页数:14
相关论文
共 50 条
  • [1] Managing recurrent/metastatic head and neck cancer in the real-world: Paclitaxel plus Cetuximab
    Leao, I.
    Neto, R.
    Marinho, J.
    Neto, E.
    Dias, E.
    Joaquim, A.
    RADIOTHERAPY AND ONCOLOGY, 2019, 132 : 51 - 51
  • [2] REAL-WORLD EVIDENCE ON METASTATIC OR RELAPSING HEAD AND NECK CANCER
    Ronconi, G.
    Dondi, L.
    Pedrini, A.
    Piccinni, C.
    Calabria, S.
    Capponcelli, A.
    Esposito, I
    Marangolo, M.
    Martini, N.
    VALUE IN HEALTH, 2020, 23 : S454 - S454
  • [3] A retrospective study evaluating the efficacy of pembrolizumab for metastatic or locally recurrent head and neck cancer: A real-world experience
    Pirruccello, Jonathan P.
    Afzal, Muhammad Zubair
    Palmer, John P.
    Dore, Maura
    Shirai, Keisuke
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] How to treat recurrent/metastatic head and neck cancer: the economic issue in real-world practice
    Lu, Hsueh-Ju
    Chang, Peter Mu-Hsin
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 779 - 780
  • [5] Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Lafuma, A.
    Cotte, F-E.
    Le Tourneau, C.
    Emery, C.
    Gaudin, A-F.
    Torreton, E.
    Gourmelen, J.
    Bonastre, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
    Kim, Hyera
    Kwon, Minsuk
    Kim, Binnari
    Jung, Hyun Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Park, Keunchil
    Ahn, Myung-Ju
    BMC CANCER, 2020, 20 (01)
  • [7] Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
    Hyera Kim
    Minsuk Kwon
    Binnari Kim
    Hyun Ae Jung
    Jong-Mu Sun
    Se-Hoon Lee
    Keunchil Park
    Myung-Ju Ahn
    BMC Cancer, 20
  • [8] Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study
    Iglesias, Leticia
    Vilchez, Rocio
    Aguin, Santiago
    Garcia, Ramon
    Pena, Carolina
    Carral, Alberto
    Huidobro, Gerardo
    Molina, Aurea
    Gomez, JESuS GARCiA
    Covela, Marta
    Costa, Marinha
    Medina, Ana
    ANTICANCER RESEARCH, 2025, 45 (03) : 1181 - 1191
  • [9] Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
    Kariya, Shin
    Shimizu, Yasushi
    Hanai, Nobuhiro
    Yasumatsu, Ryuji
    Yokota, Tomoya
    Fujii, Takashi
    Tsukahara, Kiyoaki
    Yoshida, Masafumi
    Hanyu, Kenji
    Ueda, Tsutomu
    Hirakawa, Hitoshi
    Takahashi, Shunji
    Ono, Takeharu
    Sano, Daisuke
    Yamauchi, Moriyasu
    Watanabe, Akihito
    Omori, Koichi
    Yamazaki, Tomoko
    Monden, Nobuya
    Kudo, Naomi
    Arai, Makoto
    Yonekura, Shuji
    Asakage, Takahiro
    Fujiwara, Akinori
    Yamada, Takayuki
    Homma, Akihiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (06) : 1049 - 1056
  • [10] Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
    Shin Kariya
    Yasushi Shimizu
    Nobuhiro Hanai
    Ryuji Yasumatsu
    Tomoya Yokota
    Takashi Fujii
    Kiyoaki Tsukahara
    Masafumi Yoshida
    Kenji Hanyu
    Tsutomu Ueda
    Hitoshi Hirakawa
    Shunji Takahashi
    Takeharu Ono
    Daisuke Sano
    Moriyasu Yamauchi
    Akihito Watanabe
    Koichi Omori
    Tomoko Yamazaki
    Nobuya Monden
    Naomi Kudo
    Makoto Arai
    Shuji Yonekura
    Takahiro Asakage
    Akinori Fujiwara
    Takayuki Yamada
    Akihiro Homma
    International Journal of Clinical Oncology, 2021, 26 : 1049 - 1056